Skip to content
AnalystLens

Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2002

Filing Date
Filed March 4, 2003
Period End
December 31, 2002
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Sep ’19Sep ’19
  3. Material agreement8-K · Nov ’21Nov ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 10-K filed March 4, 2003. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. is a San Diego-based company developing drugs for neurologic and endocrine diseases.

Its 2002 results show revenues of $18.0 milliona, down from $41.2 million in 2001, driven primarily by $21.0 million of milestones achieved in 2001 under the Taisho and GSK collaborations. Research and development expenses rose to $108.9 million from $74.3 million, and the net loss widened to $94.5 million, or $3.10 per share, from $36.9 million, or $1.42 per share. The accumulated deficit reached $201.9 million, and cash, cash equivalents and short-term investments totaled $244.7 million at December 31, 2002.

The company's lead program is indiplon for insomnia, which is in Phase III trials. In December 2002, Neurocrine entered a collaboration with Pfizer on indiplon under which the company received an upfront payment of $100 millionb, expected in early 2003, and is eligible for up to $300 million in additional pre-commercialization milestones. Pfizer also committed to a secured short-term loan of up to $175 million, subject to U.S. launch and other conditions.

The company plans to file a New Drug Application for indiplon in late December 2003 or early 2004. The pipeline spans seven clinical-stage programs and nine research programs, including altered peptide ligands for multiple sclerosis and Type 1 diabetes, a CRF R1 antagonist with GlaxoSmithKline, a GnRH antagonist, and the IL-4 fusion toxin NBI-3001 for cancer.

The company states it has no product approved and expects losses to continue. Management believes existing resources, interest income and future alliance payments will fund operations for at least the next 12 months.

Key Highlights

  1. 2002 total revenues were $18.0 million, down from $41.2 million in 2001, mainly due to $21.0 million of 2001 milestones under the Taisho and GSK collaborations.
  2. Net loss was $94.5 million ($3.10 per share) in 2002, compared with $36.9 million ($1.42 per share) in 2001.
  3. Research and development expense increased to $108.9 million from $74.3 million, reflecting the indiplon Phase III program.
  4. Indiplon, for insomnia, is in Phase III; Pfizer collaboration provides a $100 million upfront payment, up to $300 million in milestones, and a loan of up to $175 million.
  5. Cash, cash equivalents and short-term investments were $244.7 million at December 31, 2002, versus $320.0 million a year earlier.
  6. Accumulated deficit reached $201.9 million; the company does not expect to be profitable in 2003.
  7. Seven programs are in clinical development, and the company has no products approved for marketing.

Frequently Asked Questions

  1. What is Neurocrine's lead product and where is it in development?

    Its lead program is indiplon, a GABA-A receptor agonist for insomnia. The filing states it is in Phase III clinical trials, with an NDA planned for late December 2003 or early 2004.

  2. What are the key terms of the Pfizer collaboration?

    Pfizer is to fund substantially all out-of-pocket costs for indiplon development, manufacturing and commercialization. Neurocrine receives an upfront payment of $100 million in early 2003, is eligible for up to $300 million in pre-commercialization milestones, and will receive a percentage of worldwide indiplon sales. Pfizer may terminate on 180 days' notice.

  3. Why did revenue decline in 2002?

    Revenue fell to $18.0 million from $41.2 million, primarily because 2001 included $21.0 million of milestones achieved under the Taisho and GSK collaborations.

  4. How long is the company's cash expected to last?

    The company believes its existing capital resources, together with interest income and future payments under its strategic alliances, will be sufficient for at least the next 12 months. It also states it may need additional funding and may seek equity or debt financing.

  5. Are there any material legal proceedings?

    Item 3 states that the company is currently not subject to any material legal proceedings.